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Abstract
Background: Even though thymic stromal lymphopoietin (TSLP) has been implicated in the development of
allergic inflammation, its influence on immune tolerance mediated by regulatory T cells (Treg) have not been
explored. We aimed to dissect the influence of TSLP on immunosuppressive activities of Treg and its potential
consequences in human allergic asthma.
Methods: In vitro culture system was utilized to study the effects of TSLP on human Treg. The functional
competency of pulmonary Treg from a cohort of 15 allergic asthmatic, 15 healthy control, and 15 non-allergic
asthmatic subjects was also evaluated by suppression assays and flow cytometric analysis.
Results: Activated pulmonary Treg expressed TSLP-R and responded to TSLP-mediated activation of STAT5. TSLP
directly and selectively impaired IL-10 production of Treg and inhibited their suppressive activity. In human allergic
asthma, pulmonary Treg exhibited a significant decrease in suppressive activity and IL-10 production compared to
healthy control and non-allergic asthmatic counterparts. These functional alterations were associated with elevated
TSLP expression in bronchoaveolar lavage fluid (BAL) of allergic asthmatic subjects. Furthermore, allergic asthmatic
BAL could suppress IL-10 production by healthy control pulmonary Treg in a TSLP-dependent manner.
Conclusions: These results provide the first evidences for a direct role of TSLP in the regulation of suppressive
activities of Treg. TSLP mediated inhibition of Treg function might present a novel pathologic mechanism to
dampen tolerogenic immune responses in inflamed asthmatic airway.
Background
Thymic stromal lymphopoietin (TSLP) was initially
identified as being involved in lymphocyte development
[1,2]. Subsequently, it was implicated in the induction of
the pro-allergic phenotype in CD4+ effector T cells
(Teff) [3]. Even though most studies to date have
focused on the indirect mediation of allergic responses
of TSLP via dendritic cells [4], it has been suggested
that TSLP could directly expand CD4+ and CD8+ Teff
[5, 6[. Recent studies revealed that TSLP could directly
drive allergic responses of CD4+ Teff [7]. Studies of
experimental models of asthma also indicated that
TSLP-R-deficient animals failed to develop airway
inflammation [4,8]. Conversely, over-expression of TSLP
appeared to aggravate asthma symptoms [9]. Altogether,
these evidences strongly suggested TSLP as a positive
modulator of Th-2-biased inflammation.
Regulatory T cells (Treg) have emerged as a key regu-
lator of inflammatory responses in allergic disorders
[10,11]. Treg are CD4+CD25hiCD127lo/-Foxp3+ cells
that possess suppressive activities against cytokine pro-
duction and proliferation of Teff [12]. In studies of
human allergic asthma (AA), decreased frequency and
diminished suppressive activity of pulmonary Treg have
been documented [13]. Furthermore, murine data sug-
gested that Treg-mediated suppression reversed airway
hyper-responsiveness, inflammation, and remodeling
[14]. Immuno-suppressive cytokines such as IL-10 and
TGF-b have been implicated in immune regulation by
Treg during airway inflammation. For instance, co-
expression of IL-10 and TGF-b by Treg allowed
complete inhibition of airway hyper-reactivity [15]. In
addition, suppression of Der-p1 and Mycobacterium
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vaccae-induced airway inflammation was dependent on
IL-10 and/or TGF-b production by Foxp3+ Treg
[16,17]. Therefore, modulation of the expression of
these effector molecules by pulmonary Treg might play
a critical role in regulating airway immune responses.
TSLP has been implicated in the development of Treg
[18]. Disruption of TSLP signaling by TLSP receptor
deletion impaired intra-thymic generation of Treg but
did not affect their peripheral repertoire [19]. Consistent
with these results, blocking TSLP-R led to a delayed
functional maturation of thymic Treg [20]. Since TSLP
and Treg have been suggested to play opposite modula-
tory roles in allergic inflammation, we aimed to explore
the potential regulatory interaction between TSLP and
Treg. Here we provided data that link TSLP signaling to
the inhibition of Treg function as well as its implications
in the context of peripheral tolerance in AA.
Methods
Human subjects
The study was approved by the Stanford Administrative
Panel on Human Subjects in Medical Research. Study
population included 15 AA subjects, 15 HC subjects, and
15 NA subjects. All subjects signed informed consent
forms before participating in the study. Asthma diagnosis
was established by evidences of episodic and partially
reversible airflow obstruction or airway hyper-respon-
siveness, and exclusion of alternative diagnoses (NHLBI
Expert Panel Report-3 2007). All patients had been fol-
lowed for at least 6 months by a board certified Asthma,
Allergy, and Immunology specialist at Stanford to ensure
the diagnosis was correct. AA subjects were distinguished
from NA subjects based on history of allergic symptoms,
elevated blood IgE levels (above 50 IU/ml), and positive
skin tests to allergens. Spirometry was performed by a
fully qualified respiratory therapist and study coordina-
tor, both of whom have over 15 years of experiences in
asthma studies. Patients with FEV1 below 60% were con-
sidered severe. Those in the range of 60%-80% were con-
sidered moderate and those with FEV1 above 80% were
considered mild. Comprehensive clinical data were col-
lected at each patient visit including history, disease
severity, medication status, common allergens, IgE level,
and FEV1 (Additional file 1, Table S1). HC were defined
as non-smoking subjects greater than 17 years of age
with a total serum IgE of less than 25 IU/ml, negative
skin testing (as compared to positive histamine control),
and no evidence of lung disease or allergic symptoms. In
addition, there was no evidence of obstructive or restric-
tive lung disease for HC on spirometry testing.
Cell isolation
BAL samples were collected with a standardized proto-
col for clinical research at Lucile Packard’s Children
Hospital. After being collected, BAL samples (approxi-
mately 3 ml for each subject) were spun down at 1800
rpm for 15 minutes. Undiluted BAL supernatants were
collected and filtered with 45 μm filters (BD Bios-
ciences) and stored at -80°C until analysis. Cell pellets
were subjected to downstream isolation. Untouched
CD3+ T cells from BAL were first isolated by depleting
B cells, monocytes/dendritic cells, NK cells, and granu-
locytes with pan T cell selection kit II (Miltenyi). CD4+
T cells were then isolated from these CD3+ T cells with
CD4-microbeads (Miltenyi). Circulating CD4+ T cells
were isolated from peripheral blood by CD4+ T cell
Rosette kit (Stemcell) to deplete other cell lineages
including B cells, monocytes/dendritic cells, NK cells,
granulocytes, and non CD4+ T cells. Purified CD4+ T
cell fraction, which contained virtually no DR+ antigen
presenting cells (data not shown), was stained with
CD25 (BD Biosciences) and CD127 (Biolegend) antibo-
dies and sorted for CD4+CD25hiCD127lo/- Treg and
Teff. Cells were rested in RPMI + 10% FBS + 1% L-Glu-
tamine (complete media) after isolation. All procedures
were performed with manufacturers’ standard protocols.
Cell stimulation
For cytokine priming experiments, cells were cultured at
1*105 cells per ml for 18 hours at 37°C in complete
media in the presence or absence of 50 pg/ml recombi-
nant IL-2, IL-7, and TSLP (Peprotech). For BAL incuba-
tion, pulmonary Treg from the same HC subject were
cultured at 1*105 cells per 900 μl for 18 hours at 37°C
in complete media in the presence of BAL from differ-
ent AA and NA subjects. 100 μL of BAL supernatants
were added to 900 μl of cell suspension. To determine
the role of IL-10 in Treg-mediated suppression, recom-
binant IL-10 (Peprotech) or IL-10-blocking antibody
(R&D) was added to suppression assays at different
doses. Optimal volumes of BAL and cytokine/blocking
antibody concentrations were experimentally deter-
mined. For neutralization experiments, blocking TSLP-R
and isotype control antibody (R&D) were introduced to
cell cultures at 10 μg/ml for 0.5 hours at 37°C before
BAL supernatants were added. Optimal concentrations
of blocking reagents were experimentally determined or
used at doses recommended by the manufacturers.
Immune phenotyping via FACS and ELISA
Phenotypes of immune cells were detected with antibo-
dies against CD3, CD4, CD25, CD127, Foxp3, CTLA-4,
LAG-3, OX40, and CD40L (Biolegend). For cytokine sti-
mulation, Treg and Teff were cultured at 1*105 cells per
ml for 2 hours after isolation. After 2 hours, 1 ml of cell
suspension was stimulated with 50 ng/ml PMA (Sigma)
and 1 μg/ml Ionomycin (Sigma) for 5 hours in the pre-
sence of Brefeldin A (diluted 1× solution was added in
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the last 2.5 hours, Biolegend) for intracellular cytokine
staining or in the absence of Brefeldin A for ELISA.
Staining for membrane-bound TGF-b was performed
with standard surface staining protocols. For intracellu-
lar cytokine detection, stimulated cells were fixed and
permeablized in 200 μL of Cytofix/Cytoperm solution
(BD Biosciences) and then stained with antibodies
against IL-4, IL-10, and TNF-a (Biolegend) in Permwash
solution (BD Biosciences) in a final volume of 100 μL
(BD Biosciences). Data acquisition threshold was set on
forward scatter channel to exclude dead cells and debris
with very low size. Compensation of flow cytometric
data was performed electronically with Flow Jo (Trees-
tar) for standardization. Quantitation of secreted cyto-
kines was performed with ELISA kits for IL-4, IL-10,
TGF-b (R&D), and TSLP (eBioscience). Total protein
amount in BAL supernatants was determined by Brad-
ford assays. TSLP level in BAL samples was normalized
to total protein amount. All procedures were performed
with manufacturers’ standard protocols.
Quantitation of TSLP-R mRNA
RNA was isolated using RNeasy kits (Qiagen) according
to the manufacturer’s protocol. Similar cell numbers
(1*105 for peripheral blood cells and 5*104 for BAL
cells) were used for each subject. For cDNA synthesis,
500 ng total RNA was transcribed with cDNA transcrip-
tion reagents (Applied Biosystems) using random hex-
amers, according to the manufacturer’s protocol. Gene
expression was measured in real-time using primers and
other reagents purchased from Applied Biosystems and
Superarray. All PCR assays were performed in tripli-
cates. Data was presented as relative fold expression of
TSLP-R to the expression of the housekeeping gene
b2-microglobulin.
Detection of phosphorylated signal transducer and
activator of transcription 5 (pSTAT5)
T cells were cultured at 1*105 cells per ml in complete
media at 37°C for 18 hours after isolation. After 18
hours, 1 μl recombinant IL-2, IL-7, and TSLP (Pepro-
tech) were added to V-bottom 96-well plates and 100 μl
of cells were added to these wells with cytokines (final
cytokine concentrations were 50 pg/ml). Optimal con-
centration and stimulation duration were experimentally
determined. For ELISA, cells were lysed after being sti-
mulated for 15 minutes. Lysates were analyzed for
pSTAT5 by phospho-ELISA kits (R&D). For phospho-
flow cytometry, cells were stimulated for 15 minutes at
37°C before being fixed with 10 μL of 10% paraformal-
dehyde at 37°C. Fixed cells were washed with PBS and
permeablized with ice-cold methanol for 10 minutes.
Permeablized cells were washed again with PBS and
stained with pSTAT5 antibody (BD Biosciences). All
procedures were performed with manufacturers’ stan-
dard protocols. JAK3 inhibitor (WHI-P131, Calbiochem)
was used at optimal concentration (78 μM) recom-
mended by the manufacturer.
Suppression assays
Standard thymidine-based suppression assays were per-
formed to analyze Treg function. Treg and Teff were
cultured at 3,750 cells per well in complete media with
allogeneic irradiated CD3-depleted peripheral blood
mononuclear cells (antigen presenting cells or APC), at
37,500 cells per well (1:1:10 ratio). Assays with 1:4:10
ratio of Treg:Teff: APC were also performed. Anti-CD3
antibodies (clone UCHT1, BD) were pre-coated on
U-bottom 96 well plates at 5 μg/ml overnight at 37°C
before suppression assays were performed. Additional
media was added so the final volume in each well was
200 μl. On day 6, cells were pulsed with 1 μCi thymi-
dine (25 μl) per well and harvested on day 7 with a
Tomtec cell harvester. Thymidine incorporation was
determined using a 1450 microbeta Wallac Trilux liquid
scintillation counter. Stimulation assays were set up
similarly with allogeneic irradiated APC and only one
type of T cells. All assays were performed in triplicates.
Statistical analysis
All statistical procedures were performed with Prism
software (GraphPad). Non-parametric statistical tests
were used for analysis of cohorts with small sample
sizes (15 or less). Differences with p < 0.05 were consid-
ered statistically significant.
Results and Discussion
Activated Treg express TSLP-R and directly respond to
TSLP-mediated activation of STAT5
TSLP-R expression was first examined on purified CD3/
CD28-activated pulmonary T cell subsets from healthy
control (HC) subjects as described previously [5]. mRNA
expression of TSLP-R was significantly higher in pulmon-
ary Treg compared to pulmonary Teff (Figure 1A). Flow
cytometry (FACS) analysis showed that, compared to pul-
monary Teff, a significantly higher percentage of pulmon-
ary Treg, express TSLP-R (Figure 1A). Consistent with
these results, expression of TSLP-R positively correlated
with CD25 expression and negative correlated with CD127
expression by tri-color FACS staining (Additional file 1,
Figure S1A). TSLP signaling requires two receptor compo-
nents, IL-7Ra and TSLP-R 21, the former of which was
expressed at low level on Treg. Thus, to determine whether
this pattern of high TSLP-R and low IL-7Ra expression
was sufficient for TSLP signaling in Treg, we used phos-
pho-ELISA, which allows measurement of protein expres-
sion in rare cell subsets, to quantify the expression
of phosphorylated STAT5 (pSTAT5) by purified
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CD3/CD28-activated pulmonary Treg in response to
recombinant TSLP. Our analysis showed that level of
pSTAT5 in TSLP-stimulated pulmonary Treg was signifi-
cantly elevated compared to that of un-stimulated cells
(Figure 1B). The responsiveness of pulmonary Treg to
TSLP was confirmed with phospho-flow cytometry (Figure
1B). While TSLP and IL-7 both signal via IL-7Ra, JAK3
phosphorylation was observed only in response to IL-7
[21-23]. Thus, signaling events triggered by binding of IL7
to IL-7Ra (the only signaling component in IL-7 receptor
complex), but not binding of TSLP to TSLP-R (a part of
TSLP receptor complex, which consists of two signaling
components IL-7Ra and TSLP-R), resulted in JAK3 activa-
tion and subsequent induction of phosphorylated STAT5.
To determine which receptor component (IL-7Ra vs.
TSLP-R) in TSLP receptor complex was responsible for
activation of STAT5 in response to TSLP, we introduced a
JAK3 inhibitor into the stimulation assays. Phospho ELISA
showed that in the presence of the JAK3 inhibitor, STAT5
activation was abrogated in response to IL-7 but not TSLP
(Additional file 1, Figure S1B). These results suggested that
signaling via TLSP-R, but not IL-7Ra, in response to TSLP
was likely to be required for the induction of phosphory-
lated STAT5 in Treg. Consistent with previous findings 5,
activated Teff could response to TSLP (Figure 1C). Similar
results were also observed in circulating Treg and Teff
(Additional file 1, Figure S2). Collectively, our results
demonstrated that Treg expressed functional TSLP-R and
directly responded to TSLP-mediated activation of STAT5.
TSLP-primed Treg exhibit suboptimal suppressive
activities
Subsequently, in vitro stimulation assays were utilized to
determine the effects of TSLP signaling in Treg. Purified
Figure 1 Pulmonary Treg express functional TSLP-R. A. (Top) TSLP-R expression at protein (% of positive cells) and mRNA levels in HC
pulmonary Treg and Teff (n = 14). (Bottom) Representative FACS plots of TSLP-R expression by HC pulmonary Treg and Teff. B. (Left)
Phosphorylated STAT5 (pSTAT5) expression, measured by ELISA, in HC pulmonary Treg in response to IL-2, IL-4, IL-7, and TSLP (n = 7). (Right)
Representative FACS plots of pSTAT5 expression in HC pulmonary Treg in response to different stimuli. C. pSTAT5 expression, measured by ELISA,
in HC pulmonary Teff in response to IL-2, IL-4, IL-7, and TSLP (n = 7). Wilcoxon tests were used for statistical analysis. Horizontal bars represented
median values as indicated throughout the figure.
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CD3/CD28-activated HC pulmonary Treg were incu-
bated with 50 pg/ml TSLP for 18 hours before being
subjected to downstream assays. TSLP-primed pulmon-
ary Treg did not exhibit increased proliferation (Addi-
tional file 1, Figure S3A). Expression of surface and
intracellular molecules associated with suppressive func-
tion of pulmonary Treg such as LAG-3, CTLA-4, and
Foxp3 was not significantly altered after exposure to
TSLP (Additional file 1, Figure S4). CD40L and OX40,
molecules that have been associated with TSLP-
mediated induction of pro-inflammatory cytokine pro-
duction and inhibition of IL-10 production by T cells
[24,25] were expressed at similar levels between TSLP-
primed and un-stimulated pulmonary Treg (Additional
file 1, Figure S4). To further characterize the effects of
TSLP on Treg function, we performed in vitro suppres-
sion assays to assess the ability of Treg to inhibit Teff
proliferation after they have been exposed to TSLP.
CD3/CD28-activated Treg were pre-incubated with
TSLP for 18 hours and underwent to 3 washes to
remove TSLP in the pre-incubation cultures before sub-
jected to suppression assays. We found decreased sup-
pressive activities of TSLP-primed pulmonary Treg
compared to cultures with un-stimulated pulmonary
Treg (Figure 2A). A similar effect of TSLP was observed
in circulating T cells (Additional file 1, Figure S3B, C).
Since Treg exert their suppressive activity via cell con-
tact as well as release of suppressive molecules [26-29],
we tested whether the inhibitory effects of TSLP
occurred via the former mechanism with transwell
assays. Treg were able to suppress Teff proliferation in
the presence of transwell inserts even though their sup-
pression potency decreased (Additional file 1, Figure
S3D). Interestingly, decrease in suppressive activities of
TSLP-primed Treg was also observed in the presence of
transwell inserts (Additional file 1, Figure S3D). Thus,
suppressive activity of pulmonary Treg was significantly
reduced by exposure to TSLP. This effect did not occur
via cell-contact dependent suppressive mechanisms and
was likely to be mediated via TSLP-mediated inhibition
of soluble factors produced by Treg. These results were
consistent with our previous findings which showed that
TSLP did not alter the expression of LAG-3 and CTLA-
4, molecules that are involved in cell-contact dependent
suppressive activities of Treg [30].
TSLP suppresses IL-10 production by Treg
We next explored the influence of TSLP on Treg-
derived soluble mediators and their potential association
with the TSLP-induced impairment of Treg function.
Purified CD3/CD28-activated pulmonary Treg were
incubated with 50 pg/ml TSLP for 18 hours before cyto-
kine detection. Intracellular staining showed that TSLP-
primed pulmonary Treg exhibited a significant reduction
in IL-10 expression compared to those that were not
exposed to TSLP (Figure 2B). A similar reduction in IL-
10 expression by TSLP-primed pulmonary Treg was
confirmed via ELISA (Figure 2B). Surprisingly, this effect
was only present in the pulmonary Treg subset as simi-
lar TSLP-priming experiments of pulmonary Teff
showed no significant changes in IL-10 expression by
these cells (Figure 2B). Furthermore, no inhibitory
effects of TSLP on the production of immunosuppres-
sive cytokines TGF-b expression by pulmonary Treg
was not observed (Additional file 1, Figure S5A). TSLP
also did not enhance the production of pro-inflamma-
tory cytokines IL-4 and TNF-a in pulmonary Treg and
Teff (Additional file 1, Figure S5A, B). We also exam-
ined the priming effects of TSLP on circulating T cell
subsets and found that TLSP was also able to suppress
their IL-10 production (Additional file 1, Figure S6).
Consistent with our findings on pulmonary cells, this
inhibitory effect of TSLP on IL-10 production was speci-
fic to circulating Treg but not Teff (Additional file 1,
Figure S6). Altogether, these findings suggested that
TSLP directly inhibited IL-10 production by human
Treg.
To determine whether IL-10 inhibition was involved
in TSLP-induced impairment of Treg function, we
attempted to rescue the reduced suppression of Teff
proliferation mediated by TSLP-primed Treg with exo-
genous IL-10. Addition of recombinant IL-10 to sup-
pression assays with TSLP-primed Treg significantly
reduced thymidine uptakes in these cultures (Figure 2C,
Additional file 1, Figure S7A). Conversely, blocking IL-
10 by neutralizing antibodies in suppression assays with
Treg that were not exposed to TSLP significantly
increased cell proliferation (Figure 2C, Additional file 1,
Figure S7B). Altogether, these results demonstrated that
TSLP-mediated inhibition of Treg function might be
contributed by their suppressive effects on IL-10 pro-
duction of Treg.
Reduced function of allergic asthmatic pulmonary Treg
was associated with elevated airway TSLP
To explore the potentially pathological role of TSLP-
mediated inhibition of Treg function, we next examined
the interaction between TSLP and Treg in allergic
asthma. Elevated TSLP expression has been observed in
bronchoaveolar lavage fluid (BAL) of allergic asthmatic
(AA) subjects [31,32]. Thus, it is likely that AA pulmon-
ary Treg function might be influenced by elevated
expression of BAL TSLP. Pulmonary Treg from HC,
AA, and non-allergic asthmatic (NA) subjects were puri-
fied and subjected to in vitro functional assays (Addi-
tional file 1, Figure S8A). AA pulmonary Treg activated
with PMA and Ionomycin showed a significant decrease
in IL-10 expression compared to HC and NA
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Figure 2 TSLP inhibits suppressive activity and IL-10 production by Treg. A. Suppressive activity of un-stimulated vs. TSLP-primed HC
pulmonary Treg against Teff proliferation (n = 8) represented as thymidine counts in suppression assays (left) and percentage suppression of Teff
proliferation (right). Percentage suppression of Teff proliferation was calculated by percentage decrease in thymidine uptake in co-cultures of Teff
and Treg compared to cultures of Teff alone. B. (Top) Representative FACS plots of IL-10 production by PMA/Ionomycin (PMA/I) activated HC
pulmonary Treg after being primed with IL-2, IL-7, and TSLP. (Middle) Expression of IL-10 by PMA/I activated HC pulmonary Treg after being
primed with different cytokines (n = 7). (Bottom left) Representative FACS plots of IL-10 production by PMA/Ionomycin (PMA/I) activated HC
pulmonary Teff after being primed with TSLP. (Bottom right) Expression of IL-10 by PMA/I activated HC pulmonary Teff after being primed with
TSLP (n = 7). Data represented intracellular flow cytometric and ELISA results. C. (Top) Effects of exogenous IL-10 on suppressive activity of TSLP-
primed HC pulmonary Treg against Teff proliferation (n = 7). (Bottom) Effects of neutralizing antibodies against IL-10 on suppressive activity of
HC pulmonary Treg against Teff proliferation (n = 7). Data were represented as thymidine uptake in suppression assay cultures (left) as well as
percentage suppression of Teff proliferation (right). Wilcoxon tests were used for statistical analysis. Bar graphs and horizontal bars represented
median values as indicated throughout the figure.
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counterparts (Figure 3A). No significant changes in IL-
10, TNF-a production by pulmonary Teff; and IL-4,
TNF-a, and TGF-b expression by pulmonary Treg were
observed among 3 subject groups (Additional file 1, Fig-
ure S8B). We also observed an increase in cell prolifera-
tion in suppression assays with AA pulmonary Treg and
autologous Teff compared to assays with HC and NA
cells (Figure 3B). Furthermore, in allogeneic suppression
assays, AA pulmonary Treg showed a significant
decrease in suppressive activity against HC pulmonary
Teff compared to HC pulmonary Treg (Figure 3C). On
the other hand, HC pulmonary Treg suppressed the
proliferation of AA and HC pulmonary Teff equivalently
(Figure 3C). Collectively, these results suggested the pre-
sence of defective IL-10 production and suppressive
function by AA pulmonary Treg.
Elevated expression of TSLP in AA BAL is necessary for its
suppressive effects on Treg function
Consistent with previous findings, we found elevated
expression of TSLP in AA BAL (Figure 4A). Elevated
BAL TSLP expression was significantly correlated with
reduced IL-10 expression and suppressive function of
pulmonary AA Treg (Figure 4B). These results thus sug-
gested that the selective dysfunction in IL-10 production
by pulmonary Treg in AA might be associated with in
vivo priming of these cells by TSLP. We next examined
whether BAL from AA subjects with high concentra-
tions of TSLP could induce functional changes in HC
pulmonary Treg as previously seen with recombinant
TSLP. BAL samples from AA subjects with highest
levels of TSLP were selected for this experiment. BAL
supernatants were introduced to CD3/CD28 activated
HC pulmonary Treg cultures at a 1:10 volume ratio for
18 hours and Treg were subsequently analyzed for IL-10
production. Surprisingly, we found that HC pulmonary
Treg incubated with AA BAL showed significantly
decreased expression of IL-10 (Figure 4C). In contrast,
in similar priming experiments, BAL samples from NA
subjects failed to inhibit IL-10 production by HC pul-
monary Treg (Figure 4D). Furthermore, this reduction
in IL-10 expression by HC pulmonary Treg mediated by
AA BAL was reversed by neutralizing TSLP with 10 μg/
ml of a blocking antibody against TSLP-R (Figure 4C).
On the other hand, parallel cultures with low-endotoxin
isotype control antibodies at a similar concentration
failed to reverse the inhibition of IL-10 production of
Treg by AA BAL (Figure 4C). Altogether, these results
showed that IL-10 production by pulmonary HC Treg
could be inhibited by exposure to AA-airway-derived-
TSLP.
It has been well established that TSLP is a master reg-
ulator of airway inflammation because of its abundant
expression in airway epithelial cells as well as its ability
to instruct antigen presenting cells to prime the devel-
opment of pathogenic Th-2 helper T cells. Here we
showed that functional TSLP-R was expressed on Treg
from both blood and pulmonary compartments.
Furthermore, TSLP directly activated the signal-transdu-
cing molecule STAT5 by Treg and suppressed their
suppressive activities and production of the immunosup-
pressive cytokine IL-10. Our results thus pointed to a
potentially novel mechanism by which TSLP might
directly dampen tolerogenic immune responses of Treg,
and subsequently prolong the course of inflammation.
TSLP signaling pathway resembles that of a cytokine
family, including IL-2, IL-7, and IL-15, which all acti-
vates STAT5. Surprisingly, unlike TSLP, cytokines such
as IL-2 and IL-15 have been reported to enhance IL-10
production by Treg [33,34]. Thus, distinctions in signal-
ing pathways downstream of TSLP-R-TSLP ligation with
respect to the activation of intracellular signaling mole-
cules other than STAT5 might be required for the inhi-
bition of Treg function by TSLP. In our study, the
inhibitory effect of TSLP on IL-10 production was speci-
fic to Treg but not Teff. This result might be explained
by potential differences in signaling circuitries between
Treg and Teff, which have been observed in AKT/
mTOR cascade [35]. Proteomic analysis of intracellular
signaling molecules in Treg and Teff is underway in our
laboratory to provide further insights to this
phenomenon.
Contrary to a previous report which showed that
TSLP could enhance IL-4 production by Teff isolated
from allergen-sensitized mice [7], we did not find a
modulatory role of TSLP on IL-4 production by Teff. It
is worth noting that antigen presenting cells, which
include monocytes and dendritic cells, were depleted in
our culture system while present in theirs. Therefore, it
was possible that the ability of TSLP to stimulate IL-4
production by Teff required cross-talk between dendritic
cells and TSLP-primed Teff even in the absence of
direct TSLP-dendritic cell interaction. In addition, Jiang
et al showed that blocking TSLP reduced thymic Foxp3
expression [36]. However, we did not find a modulatory
role of TSLP on the expression of Foxp3 by peripheral
Treg. Thjs discrepancy might be due to changes in
microenvironments in the thymus vs. peripheral tissues
with respect to the presence of different cellular subsets
and cytokines, which may have an impact on Treg
homeostasis. Alternatively, modulation of Foxp3 expres-
sion in Treg by TSLP might be temporally regulated:
naïve thymic derived Treg, but not circulating/tissue
resident Treg, might be susceptible to TSLP-mediated
up-regulation of Foxp3.
Our study also showed an association between TSLP-
Treg interaction and defective function of pulmonary
Treg in human AA. Pulmonary Treg showed decreased
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Figure 3 Decreased IL-10 production and suppressive function of allergic asthmatic pulmonary Treg. A. (Top) IL-10 expression by PMA/I
activated pulmonary Treg from AA, HC, and NA subjects (n = 13). Data represented intracellular flow cytometric and ELISA results. (Bottom)
Representative FACS plots of IL-10 expression by pulmonary Treg from different subject groups. B. Suppressive activity of pulmonary Treg against
autologous Teff from AA, HC, and NA subjects represented as thymidine counts in suppression assays (n = 13). C. Allogeneic suppression assays
with pulmonary T cells from AA and HC subjects (n = 7). Treg and Teff were cultured at 1:1 and 1:4 ratios. Kruskal Wallis tests (A, B) and
Wilcoxon tests (C) were used for statistical analysis. Horizontal bars represented median values as indicated throughout the figure.
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IL-10 production, which was correlated with the
increased expression of TSLP in BAL of these subjects.
Consistent with the potential role of TSLP in the sup-
pression of IL-10 by pulmonary AA Treg, we showed
that TSLP derived from BAL of AA subjects was neces-
sary for the direct suppression of IL-10 production by
HC Treg in vitro. Alternatively, decreased IL-10 produc-
tion might result from in vivo exposure of AA Treg to
different stimuli in AA airway and interaction among
TSLP, pulmonary dendritic cells, and pulmonary Treg,
respectively. A previous study showed that defective IL-
10 production was observed on steroid-resistant asth-
matic subjects which could be pharmacologically
reversed by calcitriol [37]. In this study, the population
of regulatory T cells being examined was IL-10 produ-
cing CD4+ T cells (Tr1). Thus, it is not known whether
IL-10 production by natural Foxp3-expressing Treg is
also defective. Our preliminary studies showed that ster-
oid-resistant asthmatics also had elevated TSLP levels in
their BAL (unpublished observations), suggesting that
this increased expression of TSLP might also have an
inhibitory effect on expression of IL-10 by natural Treg.
Studies to elaborate on these findings as well as to char-
acterize the role of TSLP on IL-10 producing CD4+
T cells (Tr1) and the ability of calcitriol to reverse these
effects of TSLP on Treg production of IL-10 are under-
way in our laboratory.
Defective IL-10 production by pulmonary Treg was
found only in AA but not NA subjects. These results
were consistent with previous observations of immuno-
logical differences in these two sub-types of asthma [38].
Nevertheless, our data did not rule out the possibility
that pulmonary Treg exhibit distinct suboptimal regula-
tory functions in other allergic and pulmonary diseases.
Figure 4 Impaired allergic asthmatic pulmonary Treg function is associated with elevated airway TSLP. A. TSLP expression in BAL of AA,
HC, and NA subjects (n = 15). B. Correlation of TLSP levels in BAL of AA subjects with IL-10 production and suppression activity of AA
pulmonary Treg (n = 13). Straight lines represented best-fitted lines. Dotted lines represented 95% confident intervals. C. (Top) Effects of blocking
TLSP-R antibodies on AA BAL-mediated inhibition of IL-10 production by HC pulmonary Treg (n = 5). (Bottom) Representative FACS plots of IL-10
production by HC pulmonary Treg in different stimulatory conditions. D. Effects of NA BAL on IL-10 production by HC pulmonary Treg (n = 5).
Data represented intracellular flow cytometric and ELISA results. Kruskal Wallis tests (A), Spearman tests (B) and Wilcoxon tests (C) were used for
statistical analysis. Horizontal bars represented median values as indicated throughout the figure.
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A potential explanation is that each disease possesses a
signature inflammatory environment. Thus, the effects
of inflammatory cytokine milieu of each disease on pul-
monary Treg function might very well be different.
Modulation of TSLP signaling has been shown to be
influential to airway inflammation in experimental mod-
els of asthma [39]. Blockade of TSLP-R suppressed aller-
gic inflammation by altering dendritic cell function.
Deletion of an intracellular regulator of TSLP produc-
tion, SOCS7, also led to increased allergic phenotype
[40]. Along with these results, our data suggest that,
besides preventing airway inflammation, TSLP-targeted
therapies might also be beneficial in modulating
immune tolerance by Treg in allergic diseases.
Conclusions
Our study presents a potentially novel antigen-present-
ing-cell-independent mechanism by which TSLP might
contribute to the exacerbation of airway inflammation
by directly inhibiting tolerogenic immune responses of
pulmonary Treg.
Additional file 1: Supplementary Figures and Table. The file includes
Figures S1-8 and Table S1.
Abbreviations
HC: healthy controls; AA: allergic asthmatics; NA: non-allergic asthmatics;
Treg: CD4+CD25hiCD127lo/-regulatory T cells; Teff: CD4+CD25-T cells; TSLP:
thymic stromal lymphopoietin; pSTAT5: phosphorylated signal transducer
and activator of transcription 5; BAL: bronchoaveolar lavage fluid; PBMC:
peripheral blood mononuclear cells; FEV1: forced expiratory volume in 1
second; FACS: fluorescent activated cell sorting; MFI: mean fluorescence
intensity.
Acknowledgements
The study was supported by grants from the Mary Hewitt Loveless
Foundation, the Parker B. Francis Foundation, and the American Academy of
Allergy, Asthma, and Immunology. None of the authors have conflicting
financial interests. We are grateful to the asthmatic and healthy subjects
who provided samples for the study.
Authors’ contributions
KDN designed the study and wrote the article. KCN oversaw the project and
recruited study subjects. KDN, KCN, and CV performed experiments and
analyzed the data. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 January 2010 Accepted: 15 March 2010
Published: 15 March 2010
References
1. Vosshenrich CA, Cumano A, Müller W, Di Santo JP, Vieira P: Thymic
stromal-derived lymphopoietin distinguishes fetal from adult B cell
development. Nat Immunol 2003, 4:773-779.
2. Al-Shami A, et al: A role for thymic stromal lymphopoietin in CD4(+) T
cell development. J Exp Med 2004, 200:159-168.
3. Soumelis V, et al: Human epithelial cells trigger dendritic cell mediated
allergic inflammation by producing TSLP. Nat Immunol 2002, 3:673-680.
4. Zhou B, et al: Thymic stromal lymphopoietin as a key initiator of allergic
airway inflammation in mice. Nat Immunol 2005, 6:1047-1053.
5. Rochman I, Watanabe N, Arima K, Liu YJ, Leonard WJ: Cutting edge: direct
action of thymic stromal lymphopoietin on activated human CD4+ T
cells. J Immunol 2007, 178:6720-6724.
6. Akamatsu T, et al: Human TSLP directly enhances expansion of CD8+ T
cells. Clin Exp Immunol 2008, 154:98-106.
7. He R, et al: TSLP acts on infiltrating effector T cells to drive allergic skin
inflammation. Proc Natl Acad Sci USA 2008, 105:11875-11880.
8. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ: A role for TSLP
in the development of inflammation in an asthma model. J Exp Med
2005, 202:829-839.
9. Zhang Z, et al: Thymic stromal lymphopoietin overproduced by
keratinocytes in mouse skin aggravates experimental asthma. Proc Natl
Acad Sci USA 2009, 106:1536-1541.
10. Akdis CA, Akdis M: Mechanisms and treatment of allergic disease in the
big picture of regulatory T cells. J Allergy Clin Immunol 2009, 123:735-746.
11. Herrick CA, Bottomly K: To respond or not to respond: T cells in allergic
asthma. Nat Rev Immunol 2003, 3:405-412.
12. Miyara M, Sakaguchi S: Natural regulatory T cells: mechanisms of
suppression. Trends Mol Med 2007, 13:108-116.
13. Hartl D, et al: Quantitative and functional impairment of pulmonary CD4
+CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol
2007, 119:1258-1266.
14. Kearley J, Robinson DS, Lloyd CM: CD4+CD25+ regulatory T cells reverse
established allergic airway inflammation and prevent airway remodeling.
J Allergy Clin Immunol 2008, 122:617-624.
15. Presser K, et al: Coexpression of TGF-beta1 and IL-10 enables regulatory
T cells to completely suppress airway hyperreactivity. J Immunol 2008,
181:7751-7758.
16. Zuany-Amorim C, et al: Suppression of airway eosinophilia by killed
Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat
Med 2002, 8:625-629.
17. Hammad H, et al: Activation of the D prostanoid 1 receptor suppresses
asthma by modulation of lung dendritic cell function and induction of
regulatory T cells. J Exp Med 2007, 204:357-367.
18. Watanabe N, et al: Hassall’s corpuscles instruct dendritic cells to induce
CD4+CD25+ regulatory T cells in human thymus. Nature 2005,
436:1181-1185.
19. Jiang Q, Coffield VM, Kondo M, Su L: TSLP is involved in expansion of
early thymocyte progenitors. BMC Immunol 2007, 8:11.
20. Mazzucchelli R, et al: Development of regulatory T cells requires IL-
7Ralpha stimulation by IL-7 or TSLP. Blood 2008, 112:3283-3292.
21. Pandey A, et al: Cloning of a receptor subunit required for signaling by
thymic stromal lymphopoietin. Nat Immunol 2000, 1:59-64.
22. Park LS, et al: Cloning of the murine thymic stromal lymphopoietin
(TSLP) receptor: formation of a functional heteromeric complex requires
interleukin 7 receptor. J Exp Med 2000, 192:659-670.
23. Quentmeier H, et al: Cloning of human thymic stromal lymphopoietin
(TSLP) and signaling mechanisms leading to proliferation. Leukemia 2001,
8:1286-1292.
24. Ito T, et al: TSLP-activated dendritic cells induce an inflammatory T
helper type 2 cell response through OX40 ligand. J Exp Med 2005,
202:1213-1223.
25. Gilliet M, et al: Human dendritic cells activated by TSLP and CD40L
induce proallergic cytotoxic T cells. J Exp Med 2003, 197:1059-1063.
26. Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells
suppress polyclonal T cell activation in vitro by inhibiting interleukin 2
production. J Exp Med 1998, 188:287.
27. Shevach EM: Mechanisms of foxp3+ T regulatory cell-mediated
suppression. Immunity 2009, 30:636-645.
28. Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat
Rev Immunol 2008, 8:523-532.
29. Tang Q, Bluestone J: The Foxp3+ regulatory T cell: a jack of all trades,
master of regulation. Nat Immunol 2008, 9:239-244.
30. Wing K, Sakaguchi S: Regulatory T cells exert checks and balances on self
tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
31. Ying S, et al: Thymic stromal lymphopoietin expression is increased in
asthmatic airways and correlates with expression of Th2-attracting
chemokines and disease severity. J Immunol 2005, 174:8183-8190.
Nguyen et al. Allergy, Asthma & Clinical Immunology 2010, 6:4
http://www.aacijournal.com/content/6/1/4
Page 10 of 11
32. Ying S, et al: Expression and cellular provenance of thymic stromal
lymphopoietin and chemokines in patients with severe asthma and
chronic obstructive pulmonary disease. J Immunol 2008, 181:2790-2798.
33. Wilson MS, et al: Suppression of murine allergic airway disease by IL-2:
anti-IL-2 monoclonal antibody-induced regulatory T cells. J Immunol
2008, 181:6942-6954.
34. Lee CC, Lin SJ, Cheng PJ, Kuo ML: The regulatory function of umbilical
cord blood CD4 CD25 T cells stimulated with anti-CD3/anti-CD28 and
exogenous interleukin (IL)-2 or IL-15. Pediatr Allergy Immunol 2009,
20(7):624-632(9).
35. Zeiser R, et al: Differential impact of mammalian target of rapamycin
inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with
conventional CD4+ T cells. Blood 2008, 111:453-462.
36. Jiang Q, Su H, Knudsen G, Helms W, Su L: Delayed functional maturation
of natural regulatory T cells in the medulla of postnatal thymus: role of
TSLP. BMC Immunol 2006, 7:6.
37. Xystrakis E, et al: Reversing the defective induction of IL-10-secreting
regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest
2006, 116:146-155.
38. Nguyen KD, Vanichsarn C, Fohner A, Nadeau KC: Selective deregulation in
chemokine signaling pathways of CD4+CD25(hi)CD127(lo)/(-) regulatory
T cells in human allergic asthma. J Allergy Clin Immunol 2009, 123:933-939.
39. Shi L, et al: Local blockade of TSLP receptor alleviated allergic disease by
regulating airway dendritic cells. Clin Immunol 2008, 129:202-210.
40. Knisz J, et al: Loss of SOCS7 in mice results in severe cutaneous disease
and increased mast cell activation. Clin Immunol 2009, 132:277-284.
doi:10.1186/1710-1492-6-4
Cite this article as: Nguyen et al.: TSLP directly impairs pulmonary Treg
function: association with aberrant tolerogenic immunity in asthmatic
airway. Allergy, Asthma & Clinical Immunology 2010 6:4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Nguyen et al. Allergy, Asthma & Clinical Immunology 2010, 6:4
http://www.aacijournal.com/content/6/1/4
Page 11 of 11
